ERBB2 and invasive carcinoma: In addition, also the proportion of patients with invasive cancer who underwent axillary clearance with excision of at least 10 nodes, the proportion of patients without endocrine-sensitive invasive cancer who did not receive endocrine therapy, and the proportion of patients with HER2-invasive carcinoma (T > 1 cm or node-positive) treated with adjuvant chemotherapy failed to meet minimum EUSOMA standards.